• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Cyanotech Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events

    8/23/24 2:18:44 PM ET
    $CYAN
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CYAN alert in real time by email
    cyan20240823_8k.htm
    false 0000768408 0000768408 2024-08-22 2024-08-22
     


     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    Form 8-K
     
    Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    August 22, 2024
    Date of Report: (Date of earliest event reported)
     
    Cyanotech Corporation
    (Exact name of registrant as specified in its charter)
     
    Nevada
    (State or other jurisdiction of
    incorporation)
    000-14602
    (Commission File Number)
    91-1206026
    (IRS Employer Identification
    Number)
     
     
    73-4460 Queen Kaahumanu Highway, Suite #102, Kailua Kona, HI 96740
    (Address of principal executive offices)
     
    (808) 326-1353
    (Registrant’s telephone number)
     
    Not Applicable
    (Former name or former address, if changed since last report)
     
    Securities registered pursuant to Section 12(b) of the Act: None
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
     
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     


     
     

     
     
    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.
     
    On August 22, 2024, Cyanotech Corporation, a Nevada corporation (the “Company”), named Jennifer Rogerson, age 35, as its Vice President (“VP”) of Finance and Administration. In connection with the foregoing appointment, Felicia Ladin will remain as Chief Financial Officer (“CFO”), VP of Finance and Administration, and Treasurer until her retirement date of September 5, 2024, at which point Ms. Rogerson will become CFO, VP of Finance and Administration, and Treasurer.
     
    In connection with her appointment, Ms. Rogerson will receive an annual base salary of $195,000 and will be eligible to receive a fiscal year-end bonus per the Management Bonus Plan, subject to the Company’s pretax profit and distributed as part of an overall management bonus program. After her appointment, Ms. Rogerson will receive options to purchase 50,000 shares of the Company’s common stock (the “Options”) under the Company’s 2016 Equity Incentive Plan (the “Plan”), subject to the terms of the Plan and a Stock Option Grant Notice and Option Agreement. The exercise price per share of the Options will be the closing price on the date of grant. The Options are scheduled to vest over three years at 16,666 shares for the first year and 16,667 shares per year for the remaining two years. Ms. Rogerson will be eligible to participate in all other employee benefit plans and compensation programs that the Company maintains for salaried employees and executive officers.
     
    Ms. Rogerson has over fifteen years of experience in accounting, finance and operations. From July 2022 to May 2024, Ms. Rogerson worked at Mixhers, LLC, as CFO, Chief Operating Officer and VP of Finance, with her last position as Executive VP. From March 2014 to July 2022, Ms. Rogerson worked at BestCompany, formerly SkyRocket Media, in which she had positions of increasing responsibility including Controller, Director of Accounting and Human Resources, with her last position as VP of People and Finance. Ms. Rogerson received a Bachelor of Science degree in Accounting from Western Governors University.
     
    Item 5.07 Submission of Matters to a Vote of Security Holders.
     
    On August 22, 2024, the Company held its 2024 Annual Meeting of the Stockholders (the “Annual Meeting”). The Stockholders elected the four nominees to the Board of Directors (the “Board”) named in the proxy statement, approved the 2024 Independent Director Stock Option and Restricted Stock Grant Plan and ratified the selection of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending March 31, 2025. The final results for the votes regarding each item or proposal are set forth below. The proposals are described in detail in the Company’s proxy statement filed with the Securities and Exchange Commission on July 11, 2024.
     
    1.     To elect four directors among the nominees named in the proxy statement.
     
    Name
    Votes For
    Votes Withheld
    Broker Non-Votes
    Matthew K. Custer
    3,414,063
    123,988
    1,432,707
    Michael A. Davis
    3,405,892
    132,159
    1,432,707
    David M. Mulder
    3,432,738
    105,313
    1,432,707
    David L. Vied
    3,407,713
    130,338
    1,432,707
     
    2.     To approve the 2024 Independent Director Stock Option and Restricted Stock Grant Plan.
     
    Votes For
    Votes Against
    Abstentions
    Broker Non-Votes
    3,327,289
    201,181
    9,581
    1,432,707
     
    3.     To ratify the selection of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending March 31, 2025.
     
    Votes For
    Votes Against
    Abstentions
    Broker Non-Votes
    4,736,517
    152,983
    81,258
    -
     
     

     
     
    Item 8.01 Other Events.
     
    On August 22, 2024, the Company held the Annual Organization Meeting (the “Organizational Meeting”) of the Board. During the Organizational Meeting, it was resolved that Michael A. Davis, appointed Chairman of the Board, David M. Mulder and David L. Vied were all determined to be independent directors under Section 1.1(9) of the OTCQB Listing Rules. Also resolved was the appointment of committee members to the Board concurrent with their terms as directors, or until their earlier resignation or removal from such committee.
     
    Audit Committee
    Nominating and Corporate
    Governance Committee
    Compensation Committee
    David M. Mulder (Chair)
    Michael A. Davis (Chair)
    David L. Vied (Chair)
    David L. Vied
    David L. Vied
    Michael A. Davis
     
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
    CYANOTECH CORPORATION 
     
           
           
           
    Dated: August 23, 2024 
    /s/ Felicia Ladin
     
     
    By:
    Felicia Ladin
     
       
    Chief Financial Officer, Vice President – Finance & Administration, and Treasurer
    (Principal Financial Officer)
     
     
     
    Get the next $CYAN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CYAN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CYAN
    Leadership Updates

    Live Leadership Updates

    See more
    • Cyanotech Corporation Positions for Accelerated Global Growth in Microalgae Market with Key Leadership Appointment

      Cyanotech Corporation (Nasdaq Capital Market: CYAN), the world innovation leader in the cultivation and manufacture of microalgae for health and nutrition, including BioAstin® Hawaiian Astaxanthin and Hawaiian Spirulina Pacifica®, today announces the appointment of Collette Kakuk as Chief Strategic and Commercial Officer. Ms. Kakuk brings an impressive background in business development, strategy, and marketing to add significant value to Cyanotech's growing stable of products. Her industry experience, combined with a passionate drive for sustainable and authentic product sourcing, makes her an ideal addition to Cyanotech's executive team. Recognizing growing global interest in microalgae

      8/1/23 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care

    $CYAN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cyanotech Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2025

      Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the third quarter and first nine months of fiscal year 2025, ended December 31, 2024. Commenting on the third quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "I am pleased by our continued progress in the third quarter, with a 10.6% increase in net sales, building on the momentum that we established in the first half of the fiscal year." "As we noted last quarter, our focus on inventory management and strategic restocking has allowed us to meet demand more effec

      2/11/25 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the Second Quarter and First Six Months of Fiscal 2025

      Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the second quarter and first six months of fiscal year 2025, ended September 30, 2024. Commenting on the second quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "In prior quarters, our inventory levels were reduced to just-in-time levels to manage cash flow and strong sales in the first quarter of fiscal 2025 decreased inventory. However, mid-quarter financing allowed us to start restocking, increasing work-in-progress inventory by $1.9 million, even though finishe

      11/12/24 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the First Quarter of Fiscal 2025

      Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2025, ended June 30, 2024. Commenting on the first quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "This quarter's net sales increased 15% as compared to prior year primarily due to increased sales of Astaxanthin in both our bulk and packaged markets. As we continue to expand our product offerings, we were excited to launch our Hawaiian Spirulina® gummies in May to complement the Astaxanthin gummy product." "Our growth in sales f

      8/7/24 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care

    $CYAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Cyanotech Corporation

      SC 13D/A - CYANOTECH CORP (0000768408) (Subject)

      10/3/24 6:39:03 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cyanotech Corporation

      SC 13D/A - CYANOTECH CORP (0000768408) (Subject)

      9/12/24 12:25:52 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cyanotech Corporation

      SC 13D/A - CYANOTECH CORP (0000768408) (Subject)

      9/6/24 12:45:58 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care

    $CYAN
    Financials

    Live finance-specific insights

    See more
    • Cyanotech Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2025

      Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the third quarter and first nine months of fiscal year 2025, ended December 31, 2024. Commenting on the third quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "I am pleased by our continued progress in the third quarter, with a 10.6% increase in net sales, building on the momentum that we established in the first half of the fiscal year." "As we noted last quarter, our focus on inventory management and strategic restocking has allowed us to meet demand more effec

      2/11/25 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the Second Quarter and First Six Months of Fiscal 2025

      Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the second quarter and first six months of fiscal year 2025, ended September 30, 2024. Commenting on the second quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "In prior quarters, our inventory levels were reduced to just-in-time levels to manage cash flow and strong sales in the first quarter of fiscal 2025 decreased inventory. However, mid-quarter financing allowed us to start restocking, increasing work-in-progress inventory by $1.9 million, even though finishe

      11/12/24 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Reports Financial Results for the First Quarter of Fiscal 2025

      Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2025, ended June 30, 2024. Commenting on the first quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "This quarter's net sales increased 15% as compared to prior year primarily due to increased sales of Astaxanthin in both our bulk and packaged markets. As we continue to expand our product offerings, we were excited to launch our Hawaiian Spirulina® gummies in May to complement the Astaxanthin gummy product." "Our growth in sales f

      8/7/24 8:00:00 AM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care

    $CYAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Davis Michael A / was granted 13,158 units of Cyanotech Corporation Common Stock and bought $3,800 worth of Cyanotech Corporation Common Stock (5,000 units at $0.76) (SEC Form 4)

      4 - CYANOTECH CORP (0000768408) (Issuer)

      10/3/24 3:27:06 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Davis Michael A / bought $7,650 worth of Cyanotech Corporation Common Stock (10,000 units at $0.77) (SEC Form 4)

      4 - CYANOTECH CORP (0000768408) (Issuer)

      10/1/24 4:42:34 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Davis Michael A / bought $7,700 worth of Cyanotech Corporation Common Stock (10,000 units at $0.77) (SEC Form 4)

      4 - CYANOTECH CORP (0000768408) (Issuer)

      9/27/24 1:33:41 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care

    $CYAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CYAN
    SEC Filings

    See more
    • SEC Form 4 filed by VP of Sales Brand Jennifer Kimberly

      4 - CYANOTECH CORP (0000768408) (Issuer)

      5/21/25 1:06:36 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by VP, HR, Secretary Nordin Amy Beth

      4 - CYANOTECH CORP (0000768408) (Issuer)

      5/21/25 1:04:34 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by VP, Operations Jensen Glenn

      4 - CYANOTECH CORP (0000768408) (Issuer)

      5/21/25 1:02:39 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Leadership Update, Financial Statements and Exhibits

      8-K - CYANOTECH CORP (0000768408) (Filer)

      5/8/25 3:56:11 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by Cyanotech Corporation

      10-Q - CYANOTECH CORP (0000768408) (Filer)

      2/11/25 4:01:33 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cyanotech Corporation filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - CYANOTECH CORP (0000768408) (Filer)

      12/16/24 1:53:10 PM ET
      $CYAN
      Medicinal Chemicals and Botanical Products
      Health Care